Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease

In this multicenter, randomized trial, edoxaban monotherapy led to a lower risk of net clinical adverse events at 12 months than dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease.

​   The New England Journal of Medicine: Search Results in Cardiology